Fortress Biotech reports 2025 results; ZYCUBO approved, PRV sold for $205M

Fortress Biotech, Inc.

ZYCUBO FDA-approved for Menkes disease; Cyprium sold PRV for $205M gross, with potential $128M in sales milestones.
Checkpoint acquired by Sun Pharma; Fortress received ~$28M upfront, up to $4.8M CVR, and 2.5% royalty on UNLOXCYT.
Consolidated net loss attributable to common stockholders improved to $(1.9)M ($(0.07)/share) vs $(55.9)M ($(2.69)/share) in 2024.
Revenue rose to $63.3M in 2025 from $57.7M in 2024, driven by Journey Medical's Emrosi and dermatology portfolio.
Prepaid Oaktree loan to $15.0M outstanding; cash at $79.4M as of year-end 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fortress Biotech, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-037749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.